EUVIMEDEUVIMED entdecken
Open Access

Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma

Ehsan Malek iD, Brian Betts, Megan Herr, Marco Davila iD, Shernan Holtan iD, James J Driscoll iD, Han Yu

JCO Clinical Cancer Informatics · 2026-01 · 10 (1)

DOI: 10.1200/cci-25-00308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2026-01. Verfasst von Ehsan Malek und 6 weiteren Autor:innen. Beteiligte Einrichtung: Roswell Park Comprehensive Cancer Center, Buffalo, NY. Hauptthemen laut MEDLINE: Multiple Myeloma, Cost-Effectiveness Analysis, Cost-Benefit Analysis, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Prolonged cytopenias are a common complication after chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma, increasing the risk of severe infection. Infusion of previously collected autologous stem cells may mitigate this risk, but the clinical and economic implications of proactive collection remain uncertain. METHODS We developed an 8-year, monthly cycle Markov model simulating 10,000 patients undergoing CAR T therapy. Two strategies were compared: (1) no stem-cell boost and (2) availability of a boost for patients with prolonged cytopenias. Transition probabilities for neutropenia, infection, and infection-related mortality were derived from CARTITUDE-4 and published stem-cell boost reports. Costs included hospitalizations for severe infection and upfront stem-cell reserve collection. Deterministic and probabilistic sensitivity analyses were performed. RESULTS In the base case, universal reserve collection reduced severe infections from approximately 650 to approximately 260 per 10,000 patients and averted approximately 50 infection-related deaths. However, average per-patient costs were higher in the boost arm (approximately $19,700 US dollars [USD] v $4,500 USD), reflecting a gross reserve collection cost of $17,918 USD per patient plus lower residual infection-related hospitalization costs. Survival outcomes were similar between arms, with relapse-related mortality dominating long-term outcomes. Sensitivity analyses confirmed robustness, with hospitalization cost and reserve collection cost identified as the most influential parameters. CONCLUSION Proactive stem-cell collection for CAR T recipients reduces infectious complications and modestly improves infection-related survival but remains economically unfavorable when applied universally. A risk-adapted approach targeting patients at highest risk of prolonged cytopenias may better balance clinical benefit with cost-effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaCost-Effectiveness AnalysisCost-Benefit AnalysisImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansMarkov ChainsCytopenia

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • University Hospitals, Seidman Cancer Center, Cleveland, OH.
  • Case Comprehensive Cancer Center, Cleveland, OH.

ORCID-Profile: Ehsan Malek, Marco Davila, Shernan Holtan, James J Driscoll

Zitieren

APA

Malek, E., Betts, B., Herr, M., Davila, M., Holtan, S., Driscoll, J. J., & Yu, H. (2026). Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma. JCO Clinical Cancer Informatics, 10(1). https://doi.org/10.1200/cci-25-00308

Vancouver

Malek E, Betts B, Herr M, Davila M, Holtan S, Driscoll JJ, et al. Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma. JCO Clinical Cancer Informatics. 2026;10(1). doi:10.1200/cci-25-00308

BibTeX
@article{Malek2026,
  author = {Malek, Ehsan and Betts, Brian and Herr, Megan and Davila, Marco and Holtan, Shernan and Driscoll, James J and Yu, Han},
  title = {Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma},
  journal = {JCO Clinical Cancer Informatics},
  year = {2026},
  volume = {10},
  number = {1},
  doi = {10.1200/cci-25-00308}
}
Kostenlos starten →